Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli Isolates from U.S. Veterans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4856-4860

  Johnson, James R ^a,b   Drawz, Sarah M ^b   Porter, Stephen ^a,b   Kuskowski, Michael A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; DOXYCYCLINE; FOSFOMYCIN; MINOCYCLINE; QUINOLONE DERIVATIVE; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIUM ISOLATE; DISK DIFFUSION; EPSILOMETER TEST; ESCHERICHIA COLI; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES; VETERAN;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES; VETERANS;

EID: 84884257559     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00650-13     Document Type: Article

References (18)

1. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66:1-14.
2. Peirano G, Pitout JDD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35:316-321.
3. Prakash V, Lewis JS, Herrera ML, Wickes BL, Jorgensen JH. 2009. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum-lactamases. Antimicrob. Agents Chemother. 53:1278-1280.
4. Glasser JS, Markelz AE, Zera WC, Beckius ML, Mende K, Murray CK. 2011. Oral antibiotics for infections due to multidrug-resistant Gramnegative organisms. Scand. J. Infect. Dis. 43:649-651.
5. Owens RC, Johnson JR, Stogstill P, Yarmus L, Lolans K, Quinn J. 2011. Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death. J. Clin. Microbiol. 49:3406-3408.
6. Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. 2011. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 77:1035-1042.
7. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 4:e329. doi:10.1371/journal.pmed.0040329.
8. Lipsky BA, Byren I, Hoey CT. 2010. Treatment of bacterial prostatitis. Clin. Infect. Dis. 50:1641-1652.
9. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 732-739.
10. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thaoc L, Kuskowski M, Tchesnokova V, Sokurenko E, Johnson J. 6 August 2013, posting date. Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans. Clin. Infect. Dis. [Epub ahead of print.] doi:10.1093/cid/cit503.
11. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002-2004. Antimicrob. Agents Chemother. 53:2733-2739.
12. Clinical and Laboratory Standards Institute. 2011. M100-S21: performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Aronoff G, Bennett W, Berns J, Brier M, Kasbekar N, Mueller B, Pasko D, Smoyer W. 2007. Drug prescribing in renal failure, 5th ed. ACP Press, Philadelphia, PA.
14. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddel K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine M, Debroy C, Robicsek A, Hansen G, Urban C, Platell JL, Trott DJ, Zhanel G, Weissman SJ, Cookson B, Fang F, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko E. 2013. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J. Infect. Dis. 207:919-928.
15. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States (2007). Clin. Infect. Dis. 51:286-294.
16. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. 2003. Penetration of antimicrobial agents into the prostate. Chemotherapy 49:269-279.
17. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. 2003. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17:615-634.
18. Goto M, Sugiyama M, Nakajima S, Yamashina H. 1981. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob. Agents Chemother. 20:393-397.